Adicet bio reports positive clinical update from adi-001 phase 1 trial in relapsed/refractory non-hodgkin's lymphoma (nhl)

Menlo park, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (car) t cell therapies for cancer, today announced that an abstract detailing updated safety and efficacy data from the company's phase 1 study of adi-001 for the potential treatment of relapsed or refractory b-cell non-hodgkin's lymphoma (nhl) was made available as part of the 2022 americ
ACET Ratings Summary
ACET Quant Ranking